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Abstract
It was recently shown that a large portion of the human transcriptome can originate from within repetitive elements,
leading to ectopic expression of protein-coding genes. However the mechanism of transcriptional activation of repetitive
elements has not been definitively elucidated. For the first time, we directly demonstrate that hypomethylation of
retrotransposons can cause altered gene expression in humans. We also reveal that active LINE-1s switch from a
tetranucleosome to dinucleosome structure, acquiring H2A.Z- and nucleosome-free regions upstream of TSSs, previously
shown only at active single-copy genes. Hypomethylation of a specific LINE-1 promoter was also found to induce an
alternate transcript of the MET oncogene in bladder tumors and across the entire urothelium of tumor-bearing bladders.
These data show that, in addition to contributing to chromosomal instability, hypomethylation of LINE-1s can alter the
functional transcriptome and plays a role not only in human disease but also in disease predisposition.
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Introduction
Aberrant DNA methylation is involved in the initiation and
progression of carcinogenesis and includes both hypermethyla-
tion of CpG islands at gene promoters and global hypomethyla-
tion. While a small portion of hypomethylation occurs at gene
promoters, resulting in overexpression of certain oncogenes
[1,2], the majority occurs at repetitive elements, such as long
interspersed nuclear elements (LINE-1s or L1s) [3]. Since most
of the 500,000 copies of L1 have become nonfunctional over the
course of human evolution [4] and can no longer transpose,
genome-wide hypomethylation at L1s during tumorigenesis is
thought to contribute mainly to chromosomal instability [5]. In
mice hypomethylation of transposable elements can lead to
disruption of normal gene function [6]. Viable yellow agouti
(A
vy) mice have a retrotransposon inserted into one allele of the
agouti locus and when this retrotransposon is hypomethylated,
which can occur in utero by limiting the maternal intake of
m e t h y ld o n o r s ,i ta c t sa sa na l t e r n a t ep r o m o t e rf o ragouti.
Ectopic induction of the agouti gene results in altered coat color,
obesity, and an increased incidence of tumors [6]. While it is
well known that repetitive elements are hypomethylated in can-
cer, it has never been directly demonstrated that hypomethyla-
tion of a retrotransposon leads to ectopic gene expression in
humans.
A recent study has revealed that more than 30% of transcription
start sites in the human genome are located within repetitive
elements, with just over 7% in L1s [7]. A full length L1 sequence
(6 Kb) has a sense promoter driving transcription of its two open
reading frames and an antisense promoter driving transcription in
the opposite direction that can act as an alternate promoter for
surrounding genes [8–10]. Almost 500 of these retrotransposons
can induce ectopic gene expression in embryonic and cancerous
tissues, revealing their potential role during both development and
tumorigenesis [7]. However this study did not address the potential
mechanism of how repetitive elements become transcriptionally
active. Since the L1 promoter is a CpG island and methylated in
normal somatic tissues it seems likely that epigenetic mechanisms
are involved in its transcriptional silencing. There are many layers
of epigenetic regulation responsible for regulating expression of
single copy genes, including DNA methylation, histone modifica-
tions, and nucleosome occupancy [11]. While it is known that
unmethylated retrotransposons in Arabidopsis [12] acquire the
active histone variant H2A.Z, the chromatin structure in humans
of repetitive elements, particularly active ones, has been largely
ignored.
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individual L1s since the sequences are too similar to design
primers for one particular locus [13–15]. Therefore a direct
correlation between the epigenetic status of a specific L1 and
expression of its associated transcript has not been possible. For
the first time to our knowledge, we have elucidated the role of
epigenetics in the transcriptional activity of L1s by utilizing novel
assays capable of examining the methylation status and chromatin
structure of specific L1s and expression of alternate transcripts
originating from the L1 promoters. In addition to L1s being
hypomethylated and transcriptionally active in bladder tumors we
also found that a specific L1 located within the MET oncogene is
active across entire bladders with cancer. The clinical implication
of our finding is that surgical excision of the tumor would leave
behind large areas of the bladder that remain epigenetically
altered and express a potential oncogene. We also provide
evidence that an active L1 acquires H2A.Z and nucleosome free
regions upstream of TSSs, which has only been described
previously at single copy genes, and undergoes chromatin
remodeling from an inactive tetranucleosomal structure to an
active dinucleosomal structure.
Results
Hypomethylation of specific L1s correlates with
expression of alternate gene transcripts
To elucidate the mechanism of transcriptional activation of
repetitive elements we used the sequence of the functional
promoter of L1s to identify specific promoters potentially capable
of expressing alternate transcripts of host genes. Figure S1 contains
the genomic locations of the L1s, all of which are in an antisense
orientation to the host gene allowing for transcripts in sense
orientation to the gene’s coding sequence. Interestingly, most these
ESTs are from tumor cells. One such L1 is located within the
MET oncogene (L1-MET) [8]. Since MET is known to be
overexpressed in bladder cancer [16–18], we characterized two
L1-MET transcripts by sequencing EST clones obtained from a
bladder carcinoma cell line (GenBank accession no. BF208095)
and placenta (BX334980). Both transcripts have start sites located
in the L1 promoter, share the same reading frame as MET (Figure
S2A), and when transiently transfected into Hela cells result in
expression of truncated MET proteins (Figure S2B). Several
truncated forms of the tyrosine kinase MET, which is the
hepatocyte growth factor (HGF) receptor, are constitutively active
and promote invasion and migration through activation of a
variety of signal transduction pathways in numerous types of
carcinomas, including breast, prostate, colorectal, and lung, in
musculoskeletal sarcomas, and also in haematopoietic malignan-
cies [19,20]. Therefore hypomethylation of L1-MET could lead to
expression of a transcript that encodes a truncated and potentially
constitutively active MET protein.
To examine the methylation status at a specific L1 we designed
bisulfite-specific PCR primers with one located in the L1 promoter
and the other in the surrounding intronic region of the host gene
(Figure 1A). The L1-MET promoter was highly methylated in
normal cells and tissues, whereas 18 out of 20 of the bladder
carcinoma cell lines showed significant hypomethylation
(p,3.4610
210) (Figure 1B). We also measured methylation of
global L1s using the standard assay with two primers that anneal
within the L1 promoter (Figure 1A). We found that hypomethyla-
tion of L1s was significant (p,6.4610
25) but not as dramatic as
L1-MET hypomethylation and that the methylation pattern can
be quite different between global L1s and a specific L1, such as in
the cell lines LD137, T24, and RT4 (Figure 1B). This result clearly
shows that global L1 status does not represent the status at specific
L1s.
The transcript from the L1-MET anti-sense promoter contains
its own exons 1 and 2, referred to as L1-MET exon 1 and L1-MET
exon 2 (Figure 1A). We designed RT–PCR primers with one
primer located in either the MET exon 2 or the L1-MET exon 1
and one primer located in the shared exon 3 to examine the
expression of the host gene MET and the alternate transcript from
L1-MET, respectively (Figure 1A). We confirmed the transcription
start site of L1-MET by 59RACE in the T24 bladder carcinoma
cell line (Figure S2C) in which the L1-MET promoter is
completely unmethylated. The L1-MET transcript was lowly
expressed in one bladder fibroblast cell line (LD419) and two non-
tumorigenic urothelial cell lines, UROtsa [21] and NK2426 [22],
and highly expressed in most bladder carcinoma cell lines
(Figure 1C). L1-MET was also not expressed in normal tissues
except for placenta (data not shown). Therefore L1-MET
hypomethylation correlated with the expression of the alternate
transcript (Figure 1C). Treatment of LD419 with the demethyl-
ating agent 5-aza-deoxycytidine lead to expression of L1-MET,
suggesting that L1-MET is silenced by DNA methylation (Figure
S2D). We also designed bisulfite-specific PCR primers and RT–
PCR primers for two additional specific L1s from the list shown in
Figure S1, which were randomly selected. One L1 was located
within ACVR1C, a member of the TGF-Beta family able to induce
apoptosis [23], and the other located in RAB3IP, and a protein
whose exact function is unknown (Figure S3 and Figure S4).
Hypomethylation of these specific L1s also correlated with
expression of their associated alternate transcripts, suggesting that
DNA methylation plays a role in transcriptional silencing of
functional L1 promoters in general (Figure S3 and Figure S4).
DNA methylation silences the L1-MET promoter
The data presented thus far represents an association between
hypomethylation of an L1 promoter and ectopic expression of an
alternate transcript. To directly demonstrate that DNA methyla-
tion represses transcription of the bidirectional L1 promoter we
utilized a luciferase promoter activity assay with a pCpGL
luciferase reporter construct that has been modified to not contain
any CpG sites [24]. Therefore, after insertion of the promoter
sequence of interest the plasmid can be treated with the CpG
methyltransferase M. SssI and the methyl donor S-adenosyl-
methionine (SAM), allowing the promoter to be methylated
without affecting the plasmid backbone. We created two plasmids,
Author Summary
A surprisingly large portion of our transcriptome originates
within repetitive elements, most commonly LINE-1s.
However, the mechanism of activation has not been
definitively shown. We directly demonstrate for the first
time the causal relationship between DNA hypomethyla-
tion and transcriptional activation of LINE-1 promoters.
Hypomethylation of specific LINE-1 promoters can alter
the transcriptome, including activating an alternate
transcript of the MET oncogene, not only in primary
bladder tumors but also in premalignant urothelium across
entire bladders with tumors. Our study has important
implications for tumor biology, cancer detection, and
treatment, and it also answers the long-standing question
of whether hypomethylation of retrotransposons induces
ectopic gene expression and influences disease suscepti-
bility in humans, a phenomenon first described in agouti
mice.
Hypomethylation at a LINE-1 Activates Transcripts
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us to measure either the L1 transcriptional activity or the L1-MET
activity transcriptional activity (Figure 2A). Activity in both
directions was inhibited in the methylated plasmid (Figure 2B).
To our knowledge these data show for the first time that DNA
methylation directly suppresses transcription from L1 promoter in
both directions, indicating that the ectopic transcripts from L1s
found in cancer [7] are a result of L1 hypomethylation. The
relative activity between the two different promoters indicates that
the L1-MET promoter is much weaker than the L1 promoter.
Chromatin remodeling accompanies transcriptional
activation of L1 promoters
In addition to DNA methylation, epigenetic regulation of gene
transcription also involves chromatin structure, specifically covalent
modifications of histones, incorporation of histone variants, and
nucleosome occupancy. In mice the chromatin structure of global
L1s has been studied, but not in the promoter region [25]. Very few
studies have addressed the chromatin structure at repetitive
elements in humans. We took advantage of our ability to examine
specific L1s to analyze the chromatin remodeling that occurs
between the promoters of inactive and active repetitive elements in
humans. Using chromatin immunoprecipitation (ChIP) we found
that the level of DNA methylation at each specific L1 is inversely
proportional to the level of enrichment of active histone marks
(Figure 3A and Figure S5), and the chromatin structure at global
L1s did not correlate with the specific L1s. Comparing the structure
of the unmethylated L1-MET promoter in T24 bladder carcinoma
cells to the methylated L1-MET promoter in UROtsa urothelial
cells revealed a gain of the active marks H3K4me3 and acetylated
H3 and the histone variant H2A.Z (Figure 3A). Therefore
transcriptional activation of a repetitive element results in a similar
pattern of chromatin remodeling found in active single copy genes
such as p16 (Figure 3A) [12,26,27].
A switch from a tetranucleosome to dinucleosome
structure accompanies transcriptional activation of the
L1-MET promoter
Methylase-sensitive Single Promoter Analysis (M-SPA) has
previously been used to obtain single molecule resolution of
Figure 2. DNA methylation silences the L1-MET promoter. (A) Map of the CpG sites (represented by the lower tick marks) within the L1-MET
anti-sense promoter (ch7:116364010–116364564), which was ligated into a CpG-less luciferase vector (pCpGL) in both orientations, allowing for the
measurement of either L1-MET activity (red bars) or L1 activity (black bars). (B) The relative luciferase activity (firefly luciferase light units/Renilla
luciverase light units) is represented as the mean 6 SD and was high in the untreated vector, the methyl donor S-adenosyl-methionine (SAM) alone,
and the CpG methyltransferase (SssI) alone. When the methyltransferase enzyme and the methyl donor (SssI+SAM) were added to the luciferase
vectors together then promoter activity was silenced in both directions. The values are the average of three biological replicates. Error bars represent
the standard deviation.
doi:10.1371/journal.pgen.1000917.g002
Figure 1. Methylation and expression of L1-MET correlates in cell lines. (A) Map of alternate transcript from L1-MET. Exons are represented
by black boxes and a red box represents the specific L1. The bent arrows indicate transcriptional start sites and ATGs indicate translational start sites.
Horizontal arrows indicate the primers for PCR of bisulfite converted DNA and RT–PCR. The bisulfite-specific primers Bi-L1-59 and Bi-MET-39 were used
to amplify L1-MET for methylation analysis and Bi-L1-59 and Bi-L1-39 for global L1 methylation analysis. The RT–PCR primers, RT-L1-MET-59 and RT-
MET-39 were used to amplify cDNA of the L1-MET transcript for expression analysis and RT-MET-39 and RT-MET-59 for the full length MET expression
analysis. The lower tick marks represent each CpG site. Vertical arrows indicate the CpG sites analyzed by the Ms-SNuPE assay. (B) L1-MET methylation
(red bars) and L1 methylation (black bars) was analyzed by Ms-SNuPE in 8 normal tissues, one normal bladder fibroblast cell line (LD419), two non-
tumorigenic urothelial cell lines (UROtsa and NK2426), and 20 bladder carcinoma cell lines. Values are the average of one CpG site for L1 and an
average of two CpG sites for L1-MET from technical triplicates. Error bars represent the standard deviation. (C) Expression of L1-MET was measured
using real-time RT PCR in one normal bladder fibroblast cell line, two normal urothelial cell lines and 10 bladder carcinoma cell lines. There is clearly a
strong correlation between DNA methylation and expression in all 13 cell lines examined. Values are the average from technical duplicates. Red bars
indicate the methylation status of L1-MET, which is also represented in (B), and green bars represent the level of expression relative to GAPDH.
doi:10.1371/journal.pgen.1000917.g001
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[28]. Briefly, nuclei are isolated and treated with the CpG
methyltransferase M. SssI, followed by DNA extraction, bisulfite
conversion, and genomic sequencing of individual clones. The
resulting pattern of applied DNA methylation reveals patches of
protection, indicating the location of nucleosomes on individual
molecules. Previously, the main limitation of the M-SPA method
was that it could not be used to assess nucleosome positioning in
an endogenously methylated region. However, the enzyme M.
CviPI, which methylates GpC sites [29], can be used to avoid this
problem since endogenous GpC sites are not methylated in
humans except in the context of a GpCpG. Therefore, by
modifying our M-SPA method by using a GpC methyltransferase
we have conducted the first single molecule analysis of nucleosome
positioning at a methylated promoter and, in combination with
our ability to study specific L1s, have shown the nucleosome
occupancy at a single repetitive element in both an active and
inactive state.
The endogenously methylated L1-MET promoter in the
UROtsa immortalized urothelial cell line was completely occupied
by nucleosomes, revealing that the methylated L1-MET promoter
exists in a tetranucleosomal structure (Figure 3B). GpCpG sites
Figure 3. Chromatin remodeling occurs at an active L1-MET promoter. (A) DNA methylation at L1-MET and global L1s was determined by
pyrosequencing in the immortalized urothelial cell line UROtsa and bladder carcinoma cell line T24. Chromatin immunoprecipitation was performed
using antibodies for H3K4me3, acetylated H3, and H2A.Z. The values of the ChIP assay are the average of three experiments with technical duplicates.
Error bars represent the standard deviation, and p16 represents a single copy gene control. The presence of active histone marks was associated with
absence of DNA methylation at L1-MET in the cancer cell line. Methylase dependent single promoter analysis (MSPA) with M. CviPI, a GpC
methyltransferase, of the (B) endogenously methylated L1-MET promoter (ch7:116364020–116364664) in the UROtsa immortalized urothelial cell line
and the (C) endogenously unmethylated L1-MET promoter in T24 bladder carcinoma cells. (D) DNA methylation at L1-MET and global L1s was
determined by pyrosequencing in the colon cancer cell line HCT116 and HCT116 DKO cells (DNMT1 hypomorph/DNMT3B knockout) [31,32].
Chromatin immunoprecipitation was performed using antibodies for H2A.Z. The presence of active histone marks was associated with absence of
DNA methylation at L1-MET in the DKO cell line. Methylase dependent single promoter analysis (MSPA) with M. CviPI, a GpC methyltransferase, of the
(E) endogenously methylated L1-MET promoter in HCT116 colon cancer cells, and (F) endogenously unmethylated L1-MET promoter in HCT116 DKO
cells. White circles indicate unmethylated sites and black circles indicate methylated sites. Orange bars indicate areas of protection consistent with
the presence of a nucleosome.
doi:10.1371/journal.pgen.1000917.g003
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between endogenous CpG methylation and enzyme-induced GpC
methylation at such loci. When we performed the same assay on
T24 cells in which L1-MET is unmethylated we found a
nucleosome occupying the region downstream of each of the
two transcription start sites and no nucleosome upstream of either
(Figure 3C). We were able to confirm the results in T24 cells using
the CpG methyltransferase M. SssI, since L1-MET was not
endogenously methylated (Figure S6). However, the number and
location of CpG sites limits the resolution of this assay since the
region upstream of the L1-MET start site contains only one CpG
site. Therefore, the GpC methyltransferase allowed an increased
resolution for this method. The unmethylated MLH1 promoter
was used as a positive control for both CpG and GpC
methyltransferase activity and accessibility (data not shown).
Previous work on the MLH1 bidirectional promoter has
demonstrated that while each transcription start site loses the
nucleosome directly upstream when active (21 nucleosome), the
nucleosome directly downstream is always maintained (+1
nucleosome) [27,30]. The L1 promoter is a different type of
bidirectional promoter that generates partially overlapping sense
and antisense transcripts, commonly referred to as an antisense
promoter (ASP). The L1 ASP has room for two nucleosomes
between the two transcription start sites, therefore each start site
has its own +1 nucleosome. These two +1 nucleosomes are
maintained while the active promoter loses the 21 nucleosome at
both starts sites. Therefore the inactive L1 promoter exists in a
tetranucleosomal state (two +1 and two 21 nucleosomes) while the
active promoter exists in a dinucleosomal state (two +1
nucleosomes). In addition, when DNA methylation levels are
reduced by knocking out expression of 2 of the 3 methyltransfer-
ases responsible for maintaining DNA methylation, DNMT1 and
DNMT3B [31,32], we see acquisition of H2A.Z at L1-MET and
global L1s (Figure 3D) along with induction of expression of L1-
MET (data not shown) and nucleosome eviction at the L1-MET
promoter (Figure 3E and 3F), revealing that a switch from an
inactive tetranucleosomal structure to an active dinucleosomal
structure accompanies hypomethylation.
Many L1 promoters exist in an active chromatin structure
While a single-molecule analysis of the nucleosome occupancy
at the L1-MET promoter confirmed that an active L1 promoter
switches from a tetranucleosomal structure to a dinucleosomal
structure, we cannot generalize that other L1s exist in these states.
To do so we took a cancer cell line that has a methylated and
inactive L1-MET promoter, the colon cancer cell line HCT116,
and performed chromatin fractionation using MNase digestion
followed by sucrose gradient ultracentrifugation [33]. The
fractions were run on an agarose gel and a genomic Southern
using radioactively labeled input DNA was performed. Most of the
DNA was present in the mononucleosome and dinucleosome
fractions (Figure 4). When the same blot was probed with the L1
promoter sequence, the distribution of global L1 promoters
showed enrichment in both the dinucleosome and tetranucleo-
some fractions, indicating that other L1s besides L1-MET could
exist in an inactive tetranucleosome or active dinucleosome
structure (Figure 4).
Hypomethylation of and expression from specific L1s
occurs in bladder tumors
Since bladder tumors display both hypomethylation of L1s [34]
and overexpression of MET [16–18], our next step was to
determine whether hypomethylation of the specific L1 promoters
and their associated alternate transcripts, including L1-MET, were
Figure 4. Nucleosome eviction is a frequent occurrence at L1 promoters. Partial MNase digestion of nucleosomes was followed by
fractionation by a sucrose density gradient. When a Southern for genomic DNA was performed on the DNA in each fraction (6–16), enrichment in the
mono- and dinucleosome fractions was revealed. When a Southern for L1s was performed enrichment of L1s in the di- and tetranucleosome fractions
was found. According to our model the L1 promoters with a tetranucleosomal structure should be inactive and methylated.
doi:10.1371/journal.pgen.1000917.g004
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methylation at L1-MET and low expression in normal bladder
epithelium obtained from age-matched cancer free bladders
(Figure 5A and 5B) and significant hypomethylation of, and
expression from, L1-MET in bladder tumors (Figure 5A and 5B).
We also examined the methylation and expression of two
additional specific L1 promoters located within host genes (Figure
S7). Hypomethylation of the L1-ACVR1C and L1-RAB3IP
promoters occurred in bladder tumors (Figure S7). Therefore we
have provided the first clinical evidence that hypomethylation of
functional L1 promoters results in ectopic gene expression during
tumorigenesis.
Surprisingly, we also found hypomethylation and associated
alternate expression of L1-MET in the corresponding histologically
normal tissues from tumor-bearing bladders taken at least 5 cm
away from the tumor (p,0.0001) (Figure 5A and 5B). Hypomethy-
lation and expression of L1-MET was more prevalent in the
corresponding normal tissues than L1-ACVR1C, L1-RAB3IP (Figure
S7) [35]. Therefore, hypomethylation of L1-MET and activation of
alternate transcripts of MET occurs not only during tumorigenesis
but also in premalignant tissue. Receiver operating characteristic
(ROC)curvesforL1-METrevealedanextraordinarydegreeofboth
sensitivityand specificityfordetectingbladdertumors(AUCof0.97)
and premalignant tissue (AUCs of 0.89) (Figure S8). Since aberrant
methylation in bladder tumors can be detected in urine sediments
[36] and we are able to detect hypomethylation of L1-MET in urine
sediments of bladder cancer patients (Figure S9), a noninvasive
urine test has the potential to be developed into an assay for tumor
detection and prediction of high-risk patients.
As expected, the expression of the host gene MET was not
correlated with hypomethylation of the L1-MET promoter, since
the expression of MET is regulated by its endogenous promoter
and not by the specific L1 promoter (Figure 5A and 5C). It has
previously been shown that overexpression of MET is correlated
with global L1 hypomethylation in chronic myeloid leukemia
(CML) [14]. The biological mechanism behind this correlation is
unclear, as MET is expressed from an entirely different promoter
than L1-MET and we have shown that global L1 methylation does
not correlate with specific L1 methylation. Further, we did not find
overexpression of MET in bladder tumors, suggesting that it may
be L1-MET that is overexpressed instead since many primers used
to detect expression can amplify both products.
Hypomethylation and expression of L1-MET occurs across
the urothelium of tumor-bearing bladders
Since we observed hypomethylation at L1-MET in bladder
tissues taken at least 5 cm from tumors we collected histologically
normal tissue samples from five tumor-bearing bladders taken at
various distances and directions from the tumors to determine
whether distance has any effect on the level of hypomethylation
(Figure 6A). When compared to the average level of methylation in
normal tissues from cancer-free bladders, L1-MET was dramat-
ically hypomethylated in normal-appearing tissues across each of
the tumor-bearing bladders independent of the distance from the
site of the tumor (Figure 6B). However the normal-appearing
tissues were not significantly hypomethylated at L1-ACVR1C, L1-
RAB3IP, and global L1 (Figure S10 and Figure 6C). Bisulfite
sequencing of L1-MET in the urothelium of patients without
bladder cancer revealed only fully methylated strands while in a
patient with bladder cancer fully unmethylated strands were
present in the tumor and the corresponding normal urothelial
tissue independent of the distance from the tumor (Figure 6D and
Figure S11). A plot of the distribution of DNA strands versus the
percent of methylated sites reveals a biphasic distribution in the
patient with bladder cancer, with the majority of strands either
fully methylated or fully unmethylated (Figure S11). Our in vitro
results (Figure 2 and Figure 3) suggest that these fully
unmethylated strands found in tumor-bearing bladders have
undergone chromatin remodeling involving a switch from a
tetranucleosome to a dinucleosome structure and are transcrip-
tionally active. To our knowledge this is the first alteration, either
epigenetic or genetic, that has been found across an entire tumor-
bearing organ.
Discussion
The consequences of global hypomethylation at repetitive
elements in cancer has long been the subject of speculation
Figure 5. Methylation and expression status of L1-MET correlates in bladder tissues. Horizontal lines represent the mean and n the
number of patient samples. (A) Methylation status was analyzed by Ms-SNuPE in normal tissues (N, green), corresponding normal tissues (CN, dark
blue), and bladder tumors (T, red). Values are an average of two CpG sites. (B) Expression of the alternate transcript from L1-MET and (C) the host gene
MET, and the control gene GAPDH was measured by real-time RT–PCR. *** represents p,0.001, ** represents p,0.01, and * represents p,0.05 as
determined by the Mann-Whitney test. While there are no error bars for the clinical sample analysis due to the extremely limited amount of sample
DNA, the results show a consistent trend.
doi:10.1371/journal.pgen.1000917.g005
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activation of oncogenes. Ever since studies on viable yellow agouti
(A
vy) mice revealed that hypomethylation of a retrotransposon
could induce ectopic expression of a gene and influence disease
susceptibility [6] it has been postulated that similar events may
occur in humans. While hypomethylation during tumorigenesis
occurs quite frequently, a direct demonstration of the impact of
hypomethylation of repetitive elements on gene expression has not
been conducted. Transcriptome sequencing has recently revealed
the prevalence of transcripts originating from alternate TSS within
repetitive elements in humans, indicating a potential functional
role of activated repeats in altering gene expression [7]. Active L1s
were mostly found in embryonic and cancerous tissues, many of
which result alternate transcripts of protein-coding genes. Using
several specific L1s we have demonstrated the mechanism of
transcriptional activation and, taken together with the results of
Faulkner et al. [7], our results highlight the previously underap-
preciated impact of hypomethylation on ectopic gene expression,
possibly contributing to tumorigenesis in a synergistic or
cooperative manner (see model in Figure 7).
To elucidate the mechanism of transcriptional activation of
repetitive elements, we compared the epigenetic alterations,
including methylation status, histone modifications, and nucleo-
some positioning, that occur at a single copy of an L1 between a
transcriptionally inactive and active state. Since current methods
did not exist for such a study we employed several novel assays,
including using primers able to amplify specific L1s, enabling
methylation and ChIP assays to be performed on single copies,
and a modification of the method for determining nucleosome
positioning at a single molecule resolution, currently limited to
unmethylated CpG islands, which allowed for the determination
of nucleosome positioning in a methylated region. We were able
to show that transcription from the L1 promoter is silenced by
DNA methylation, providing direct evidence that one function
of DNA methylation is to protect the human genome from
retrotransposons.
Transcriptional activation of L1 promoters by hypomethyla-
tion results in a chromatin structure similar to that of active single
copy genes such as p16, revealing that the features of active
promoters, such as acquisition of active histone marks, H2A.Z,
and nucleosome free regions upstream of TSSs, are not restricted
to canonical gene promoters. In addition, we found that the
unique structure of the L1 promoter results in two very stable
nucleosome occupancy states, the inactive tetranucleosome
structure and the active dinucleosome structure, and that
hypomethylation could result in a switch between the two. It
has been demonstrated that tetranucleosomes form a compact
chromatin fiber [37]. Therefore, the widespread chromatin
remodeling due to global hypomethylation of L1 promoters
could contribute to chromosomal instability through the loss of
many stabilizing tetranucleosome structures.
To our knowledge we have provided the first direct evidence
that transcriptional activation of repetitive elements is caused by
hypomethylation and chromatin remodeling at their promoters,
occurs in a human diseased state, and may play a role in disease
predisposition. Specifically, hypomethylation of a L1 promoter
induces an alternate transcript of the MET oncogene in bladder
tumors and across the entire urothelium of tumor-bearing
bladders. The presence of L1-MET hypomethylation across the
entire urothelium of tumor-bearing bladders has several possible
explanations. Epigenetic alterations such as hypermethylation of
tumor suppressor genes and hypomethylation of L1s have been
found in normal epithelia adjacent to several types of tumors,
including breast [38], esophageal [39], and colon [40,41],
indicating the presence of a ‘‘field defect’’. Our data supports
the presence of an epigenetic field defect in bladders with cancer,
either due to independent events across the urothelium or clonal
expansion [42]. However, another possible explanation is that the
loss of L1-MET methylation occurred during early development
before the bladder was fully formed. While some evidence for such
abnormal epigenetic programming exists, as a recent study
revealed that people who develop bladder cancer have slightly
lower levels of global DNA methylation in their blood than healthy
control cases [43], we did not find any evidence of a loss of
methylation at global L1s or specific L1s in our patient WBC
samples (Figure S9). Another possibility, which cannot be ruled out
by this data, is that the presence of a tumor causes epigenetic
changes across the bladder.
Whatever the underlying mechanism, the modulation of gene
expression by hypomethylation of a retrotransposon such as what
occurs at the agouti locus in mice is also found in humans. This
leads to the activation of surrounding genes, which may contribute
to tumorigenesis in a synergistic or cooperative manner.
Transurethral resection of bladder tumors would leave behind
large areas of epigenetically altered urothelium, possibly contrib-
uting to the high level of recurrence of bladder cancer.
Fortunately, hypomethylation at specific L1s seems to provide a
valuable biomarker that has the potential to significantly impact
the diagnosis and treatment of bladder cancer.
Materials and Methods
Cell lines
The non-tumorigenic human urothelial cell lines UROtsa and
NK2426 and the normal fibroblast cell line LD419 have been
described previously [21,22,36]. Human bladder carcinoma cell
lines were obtained commercially (T24, J82, HT1376, SCaBER,
UM-UC-3, TCCSUP, and RT4; American Type Culture
Collection, Manassas, VA) or derived in our laboratory (prefix
LD). Cell culture, DNA and RNA purification were performed as
previously described [36]. RNA was reverse-transcribed as
previously described [36]. 59-Rapid Amplification of cDNA Ends
(RACE) to determine the 59 end of the primary transcript of L1-
MET was performed using the RLM-RACE kit (Ambion)
according to the manufacturer’s instruction. See Table S1 for
primer sequences.
Tissue collection
Tumor tissue samples were collected from the patients
undergoing cystectomy or TURBT for bladder cancer. Normal
bladder epithelium was obtained from 12 patients undergoing
radical prostatectomy for prostate cancer (aged from 50 to 80) and
Figure 6. Methylation of L1-MET across the bladder. (A) Tissue samples were taken from five patients of their tumors (red, T) and at increasing
distances from the tumor (0.5 to 2 cm) in the surrounding normal-appearing tissue in multiple directions (light blue, a to d). Additionally, distant
normal-appearing samples were taken at least 5 cm from the tumor (dark blue, C). (B) Methylation at L1-MET and (C) global L1 was measured by
pyrosequencing. The green line represents the mean methylation of normal samples from cancer-free patients. While there are no error bars for the
clinical sample analysis due to the extremely limited amount of sample DNA, the results show a consistent trend. (D) Bisulfite sequencing of L1-MET
was performed on samples from two bladder cancer-free patients (#4987 and #5240) and one bladder cancer patient (#6519). White circles
represent unmethylated CpGs and black circles represent methylated CpGs.
doi:10.1371/journal.pgen.1000917.g006
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PLoS Genetics | www.plosgenetics.org 9 April 2010 | Volume 6 | Issue 4 | e1000917Figure 7. Model of the epigenetic alterations that occur between inactive L1s and active L1s during tumorigenesis. An L1 promoter is
usually silenced by DNA methylation and has a compact chromatin structure with four nucleosomes occupying the promoter. Upon hypomethylation
during tumorigenesis the L1 promoter becomes transcriptionally active. The active promoter loses a nucleosome upstream of each of the
transcription start sites, resulting in a dinucleosome structure. The remaining nucleosomes have acetylated H3, H3K4me3, and H2A.Z. (21) represents
the nucleosome directly upstream of the transcription start site, while (+1) represents directly downstream nucleosome of transcriptional start site.
doi:10.1371/journal.pgen.1000917.g007
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cancer related deaths and 2 from deaths due to cancers other than
bladder). All of these collections took place at Norris Cancer
Hospital in IRB-approved protocols with patients’ consent.
Hematoxylin and eosin (H&E) sections marked with the location
of the adjacent urothelium or tumor were used to guide in
microdissection. DNA was bisulfite treated as previously described
[44]. RNA extraction was done using a RNAeasy Micro Kit
(Qiagen, Crawley, UK).
Quantitation of DNA methylation
Methylation-sensitive single nucleotide primer extention (MS-
SNuPE) was performed as previously described [44]. See Table S1
for primer sequences. In order to allow for a higher throughput in
methylation analysis pyrosequencing was also performed as
described previously [45]. Testing both methods on the same set
of 66 samples yielded a correlation in the methylation levels of
R=0.91 (Figure S12). For pyrosequencing, PCR was performed
on bisulfite converted DNA using a biotin-labeled 39 primer to
enable purification and denaturation of the product by Strepta-
vidin Sepharose beads and was followed by annealing of a
sequencing primer to the single-stranded PCR product. Pyrose-
quencing was performed using the PSQ HS96 Pyrosequencing
System and the degree of methylation was expressed for each
DNA locus as percentage methylated cytosines over the sum of
methylated and unmethylated cytosines. See Table S1 for primer
sequences. To analyze the methylation status of individual DNA
molecules, we cloned bisulfite PCR fragments into the pCR2.1
vector using the TOPO-TA cloning kit (Invitrogen, Carlsbad,
CA). Individual colonies were screened for the insert and the
region of interest was sequenced using M13 primers. See Table S1
for primer sequences.
Quantitative RT–PCR
Expression was determined by quantitative RT–PCR as
described previously [27]. See Table S1 for primer sequences.
Luciferase assay
The L1-MET and L1 promoters were cloned into the pCpGL
luciferase vector [24]. The portion of the L1-MET promoter
cloned was 555 bp, with 535 bp within the L1 and 20 bp within
the MET gene (ch7:116364010–564). These experiments were
performed as described previously [24].
Chromatin immunoprecipitation
ChIP was performed as described previously [27]. Briefly,
chromatin was isolated from cells and crosslinked with formalde-
hyde. The chromatin was then sonicated to less than 500 bp in
length and immunoprecipitated with an antibody to the histone
modification of interest. Enrichment was determined by RT–PCR
of the pulled down DNA. See Table S1 for primer sequences.
Methylation-dependent single promoter analysis
M-SPA was performed as described previously [28]. Briefly,
chromatin was isolated from 250,000 cells and treated for 15
minutes with 50 U of M. SssI. DNA was isolated, bisulfite
converted, and PCR fragments were cloned for sequencing of
individual molecules. In order to examine endogenously methyl-
ated promoters and increase the resolution of this method,
chromatin from 250,000 cells was treated with the enzyme M.
CviPI, which methylates GpC sites [29], for 15 minutes with
100 U.
MNase digestion and Southern blot
MNase digestion and sucrose density gradient centrifugation
were performed as described previously [33]. See Table S1 for
primer sequences for the LINE-1 promoter probe.
Statistical analyses
Significant differences in methylation and expression levels in
normal, corresponding normal, and tumor tissues were deter-
mined using a Mann-Whitney test.
Supporting Information
Figure S1 Specific L1s with alternate transcripts located in
intron of genes. Black boxes represent exons of the host gene while
red boxes represent a specific L1. The black arrow represents the
transcriptional start site of the host gene while the red arrow
represents the alternate transcriptional start site within the
potentially active L1 promoter. GenBank accession numbers for
representative alternate transcripts are followed by the number in
parentheses of similar transcripts transcribed from the individual
L1. All L1s are antisense to their host genes, yielding alternate
transcripts that are sense with their host genes.
Found at: doi:10.1371/journal.pgen.1000917.s001 (0.56 MB TIF)
Figure S2 The truncated MET protein encoded by L1-MET.
(A) The functional domains of MET include the signal peptide
(SP), sema domain at the N-terminus, the PSI domain, IPT
repeats, the transmembrane domain (TM), and the kinase domain
at the C-terminus. The structure of truncated MET proteins 1 and
2 are shown, encoded by transcripts derived from placenta
(GenBank accession no. BX334980) and a bladder carcinoma cell
line (BF208095), respectively. (B) The two L1-MET transcripts,
truncated L1-MET-1 (T-MET-1) and truncated L1-MET-2 (T-
MET-2), were cloned into a pMEV expression vector with 2 HA
tags fused at the N-terminal. Hela cells were transfected with
either the empty pMEV vector, pMEV T-MET-1, or pMEV T-
MET-2 and protein was extracted after 48 hours. The expression
of truncated MET-1 (90 kDa) and truncated MET-2 (60 kDa) was
detected by western blot using an HA antibody. (C) Results of
59RACE reveal the start site for L1-MET within the L1 element.
The transcriptional start site of L1-MET was confirmed by
59RACE in the T24 cell line which expressed L1-MET. The
underlined sequence is located inside of the LINE-1. (D) RT–PCR
analysis of reactivation of L1-MET by 1 or 3 mM of 5-Aza-CdR
treatment for 24 hours (day 3 after treatment). b-actin expression
level was used as a control.
Found at: doi:10.1371/journal.pgen.1000917.s002 (1.22 MB TIF)
Figure S3 Methylation and expression of L1-ACVR1C correlates
in cell lines. (A) Map of alternate transcripts from L1-ACVR1C.
Exons are represented by black boxes while the specific L1s are
represented by red boxes. The lower tick marks represent each
CpG site. The left bent arrow indicates transcriptional start sites
and ATGs indicate translational start sites. Green arrows indicate
the primers used to amplify the pyrosequencing product and the
black arrow in between indicates the location of the pyrosequenc-
ing primer for L1-ACVR1C. (B) L1-ACVR1C methylation (red bars)
and L1 methylation (black bars) was analyzed by pyrosequencing
in 6 normal tissues, one normal bladder fibroblast cell line
(LD419), one non-tumorigenic urothelial cell lines (UROtsa), and
10 bladder carcinoma cell lines. Values are the average of one
CpG site for L1 and an average of two CpG sites for L1-ACVR1C
from two technical duplicates. (C) Expression of L1- ACVR1C was
measured using real-time RT PCR in one normal bladder
fibroblast cell line, one normal urothelial cell line, and 10 bladder
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technical duplicates. Red bars indicate the methylation status of
L1-ACVR1C, which is also represented in (B), and green bars
represent the level of expression relative to GAPDH.
Found at: doi:10.1371/journal.pgen.1000917.s003 (0.86 MB TIF)
Figure S4 Methylation and expression of L1-RAB3IP correlates
in cell lines. (A) Map of alternate transcripts from L1-RAB3IP.
Exons are represented by black boxes while the specific L1s are
represented by red boxes. The lower tick marks represent each
CpG site. The left bent arrow indicates transcriptional start sites
and ATGs indicate translational start sites. Green arrows indicate
the primers used to amplify the pyrosequencing product and the
black arrow in between indicates the location of the pyrosequenc-
ing primer for L1-RAB3IP. (B) L1-RAB3IP methylation (red bars)
and L1 methylation (black bars) was analyzed by pyrosequencing
in 6 normal tissues, one normal bladder fibroblast cell line
(LD419), one non-tumorigenic urothelial cell lines (UROtsa), and
10 bladder carcinoma cell lines. Values are the average of one
CpG site for L1 and an average of two CpG sites for L1-RAB3IP
from two technical duplicates. (C) Expression of L1-RAB3IP was
measured using real-time RT–PCR in one normal bladder
fibroblast cell line, one normal urothelial cell line, and 10 bladder
carcinoma cell lines. Values are also the average from two
technical duplicates. Red bars indicate the methylation status of
L1-RAB3IP, which is also represented in (B), and green bars
represent the level of expression relative to GAPDH.
Found at: doi:10.1371/journal.pgen.1000917.s004 (0.88 MB TIF)
Figure S5 Chromatin remodeling occurs at active L1 promoters.
(A) DNA methylation at specific and global L1s (with p16 as a
control) was determined by pyrosequencing in the immortalized
urothelial cell line UROtsa and bladder carcinoma cell line T24.
The specific L1s had less methylation in the cancer cell line.
Chromatin immunoprecipitation was performed using antibodies
for (B) H3K4me3; (C) acetylated H3; and (D) H2A.Z. The values
of the ChIP assay are the average of three experiments with
technical duplicates. Error bars represent the standard deviation.
The presence of active histone marks was associated with absence
of DNA methylation at the specific L1s in the cancer cell line.
Found at: doi:10.1371/journal.pgen.1000917.s005 (0.67 MB TIF)
Figure S6 Chromatin remodeling occurs an active L1-MET
promoter. Nucleosome positioning in an active fully unmethylated
L1-MET promoter in T24 bladder carcinoma cells reveals a
dinucleosomal structure, as determined by both M. SssI, a CpG
methyltransferase and M. CviPI accessibility.
Found at: doi:10.1371/journal.pgen.1000917.s006 (1.29 MB TIF)
Figure S7 Methylation and expression status of specific L1s
correlates in bladder tissues. Horizontal lines represent the mean.
(A) Methylation status of L1-ACVR1C was analyzed by pyrose-
quencing in normal tissues (N), corresponding normal tissues (CN),
and bladder tumors (T). Values are an average of two CpG sites.
(B) Expression of the alternate transcript from L1-ACVR1C and
(C) the host gene ACVR1C, and the control gene GAPDH was
measured by real-time RT–PCR. *** represents p,0.001,
** represents p,0.01, and * represents p,0.05. (D) Methylation
status of L1-RAB3IP was analyzed by pyrosequencing in normal
tissues (N), corresponding normal tissues (CN), and bladder tumors
(T). Values are an average of two CpG sites. (E) Expression of the
alternate transcript from L1-RAB3IP and F. the host gene RAB3IP,
and the control gene GAPDH was measured by real-time RT–
PCR. *** represents p,0.001, ** represents p,0.01, and *
represents p,0.05 as determined by the Mann-Whitney test.
While there are no error bars for the clinical sample analysis due
to the extremely limited amount of sample DNA. the results show
a consistent trend.
Found at: doi:10.1371/journal.pgen.1000917.s007 (0.58 MB TIF)
Figure S8 ROC curves for specific L1s. (A) ROC curves using
L1-MET methylation distinguish between normal bladder tissue
(N) and corresponding normal bladder tissues (CN), N and bladder
tumors (T), and CN and T. (B) ROC curves using L1-ACVR1C
methylation, and (C) ROC curves using L1-RAB3IP methylation.
*** represents p,0.001 and * represents p,0.05.
Found at: doi:10.1371/journal.pgen.1000917.s008 (0.65 MB TIF)
Figure S9 Detection of L1-MET hypomethylation in urine
sediments of patients with bladder cancer. Bisulfite-specific primers
and a probe were designed for the MethyLight assay that amplified
only completely unmethylated strands of L1-MET. Bladder tissues
(N) from age-matched patients without bladder cancer (n=10) and
urine (N) from age-matched healthy volunteers (n=10) showed low
levels of L1-MET hypomethylation. However, urine (n=20) from
patientswithTCCshowedhighlevelsofL1-METhypomethylation,
which was specific to the bladder since it was not detected in their
white blood cells (WBC) (n=20). Unmethylated levels (Y axis)
indicate the Percent of fully Unmethylated Reference (PUR) values.
Found at: doi:10.1371/journal.pgen.1000917.s009 (0.30 MB TIF)
Figure S10 Methylation of specific L1s across the bladder. (A)
Tissue samples were taken from five patients of their tumors (red, T)
and at increasing distances from the tumor (0.5 to 2 cm) in the
surrounding normal-appearing tissue in multiple directions (light
blue, a to d). Additionally, distant normal-appearing samples were
taken atleast5 cmfrom thetumor(dark blue,C).(B) Methylation at
L1-ACVR1C and (C) L1-RAB3IP was measured by pyrosequencing.
The green line represents the mean methylation of 12 normal
samples from cancer-free patients. While there are no error bars for
the clinical sample analysis due to the extremely limited amount of
sample DNA. the results show a consistent trend.
Found at: doi:10.1371/journal.pgen.1000917.s010 (1.62 MB TIF)
Figure S11 Bisulfite sequencing of L1-MET. Biphasic distribu-
tion of L1-MET methylation status in corresponding tissue from a
patient with bladder cancer is revealed by plotting the number of
DNA strands by the percent of CpG sites methylated.
Found at: doi:10.1371/journal.pgen.1000917.s011 (0.18 MB TIF)
Figure S12 Ms-SNuPE and pyrosequencing yield similar methyl-
ation results. While both Ms-SNuPE and Pyrosequencing are
quantitative assays, Pyrosequencing is much more high throughput.
Therefore, we developed a Pyrosequencing assay for the rest studies.
(A) We measured 4 CpG sites by Pyrosequencing assay in contrast
with the 2 CpG sites by Ms-SNuPE. (B) We randomly chose 66
samples previously analyzed by Ms-SNuPE to perform Pyrosequenc-
i n go na n dt h er e s u l t sa r ev e r ys i m i l a rf r o mb o t ha s s a y s( R=0 . 9 1 ) .
Found at: doi:10.1371/journal.pgen.1000917.s012 (0.42 MB TIF)
Table S1 Primer sequences.
Found at: doi:10.1371/journal.pgen.1000917.s013 (0.08 MB
DOC)
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